US 11,913,950 B2
Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
Anthony Marotta, Burnaby (CA)
Assigned to AUGUREX LIFE SCIENCES CORP.
Filed by Augurex Life Sciences Corp., Vancouver (CA)
Filed on Nov. 19, 2018, as Appl. No. 16/195,582.
Application 16/195,582 is a continuation of application No. 14/353,281, granted, now 10,132,806, previously published as PCT/CA2012/050748, filed on Oct. 19, 2012.
Claims priority of provisional application 61/550,046, filed on Oct. 21, 2011.
Prior Publication US 2019/0310249 A1, Oct. 10, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/53 (2006.01); G01N 33/564 (2006.01); G01N 33/68 (2006.01); C07K 14/47 (2006.01); G01N 33/543 (2006.01)
CPC G01N 33/564 (2013.01) [C07K 14/47 (2013.01); C07K 14/4713 (2013.01); G01N 33/54306 (2013.01); G01N 33/6893 (2013.01); G01N 2440/18 (2013.01); G01N 2800/105 (2013.01)] 8 Claims
 
1. A autoantibodies against a citrullinated 14-3-3 protein or fragment thereof in a subject comprising
i) obtaining a biological sample from a subject suspected of having or at risk for developing rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, and psoriatic arthritis;
ii) contacting said biological sample from said subject with at least one citrullinated 14-3-3 protein or fragment thereof under a condition suitable for the formation of at least one immune complex between the citrullinated 14-3-3 protein or fragment thereof and autoantibodies against the citrullinated 14-3-3 protein or fragment thereof that may be present in the biological sample; and
iii) detecting the presence of immune complexes between the citrullinated 14-3-3 protein or fragment thereof and autoantibodies against the citrullinated 14-3-3 protein or fragment thereof;
wherein the citrullinated 14-3-3 protein or fragment thereof comprises a citrulline residue at a position selected from the group consisting of position 4, position 12, position 19, position 42, position 61, position 86 and position 227 of SEQ ID NO: 5; or comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-22.